Sage Therapeutics Inc (FRA:SG7)
€ 6.826 -1.132 (-14.22%) Market Cap: 365.22 Mil Enterprise Value: -151.29 Mil PE Ratio: 0 PB Ratio: 0.72 GF Score: 48/100

SAGE Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 03:30PM GMT
Release Date Price: €47.8 (+1.70%)
Brian Abrahams
RBC Capital Markets - Analyst

I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. We're really pleased to have with us our next presenting company, Sage Therapeutics. Obviously, a very eventful time for Sage, so thanks so much for being here. I know you guys are very busy.

Representing Sage, we have their Chief Business Officer, Chris Benecchi; their Chief Financial Officer, Kimi Iguchi; and their Chief Scientific Officer, Al Robichaud. Thank you. Thanks again.

Al Robichaud
Sage Therapeutics, Inc. - Chief Scientific Officer

Thank you.

Kimi Iguchi
Sage Therapeutics, Inc. - CFO

Great.

Questions & Answers

Brian Abrahams
RBC Capital Markets - Analyst

So maybe starting with just what's, I think, on the top of most people's minds, zuranolone and the ongoing review process. Can you give us any sense, maybe generally speaking, on just how the FDA's review process for zuranolone's been going and your sense overall

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot